Compare NTCT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | NUVB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1999 | N/A |
| Metric | NTCT | NUVB |
|---|---|---|
| Price | $39.64 | $5.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $31.00 | $11.38 |
| AVG Volume (30 Days) | 665.7K | ★ 4.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.39 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $891,820,000.00 | N/A |
| Revenue This Year | $6.02 | $203.82 |
| Revenue Next Year | $2.55 | $58.18 |
| P/E Ratio | $30.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.40 | $1.87 |
| 52 Week High | $43.80 | $9.75 |
| Indicator | NTCT | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 65.32 |
| Support Level | $38.38 | $5.22 |
| Resistance Level | $40.92 | $6.06 |
| Average True Range (ATR) | 1.44 | 0.39 |
| MACD | -0.48 | 0.07 |
| Stochastic Oscillator | 20.27 | 93.28 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.